Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kegang Liyan Oral Solution
- Development stage
- Phase 4
- Lead developer
- Guangzhou Wanglaoji Pharmaceutical
- Administration
- Oral
01
Overview
Kegang Liyan Oral Solution is a Traditional Chinese Medicine (TCM) developed by Guangzhou Wanglaoji Pharmaceutical for the treatment of acute pharyngitis, specifically targeting the Wind-Heat Syndrome according to TCM diagnostic principles. It is formulated as an oral solution and is currently undergoing Phase 3 clinical evaluation in China (CTR20254213) to assess its efficacy and safety in adult patients compared to a placebo. The product is intended to alleviate symptoms such as sore throat, congestion, and inflammation associated with acute pharyngeal infections through a multi-component herbal approach.
- Brand names
- Kegang Liyan Oral Solution
- Other names
- 渴刚利咽口服液
02
Targets
MMP9 (Matrix metalloproteinase-9)NF-κBTLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Kegang Liyan Oral Solution.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kegang Liyan Oral Solution.